Somatropin

Somatropin is the reference molecule for the entire GH-axis class. It is also the molecule whose regulatory and clinical landscape is most distinct from the secretagogues — well-characterized over four decades, with regulator-approved indications for specific deficiency populations, deeply studied in randomized controlled trials, and uniquely restricted in U.S. law against off-label use.

The approved-indication map is precise. The FDA has approved somatropin products for pediatric growth hormone deficiency, adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, small-for-gestational-age children who fail to catch up, chronic kidney disease in children, and HIV-associated wasting; a separate somatropin product (Zorbtive) is approved for short bowel syndrome on parenteral support. Approved products include the daily-injection somatropins (Humatrope, Genotropin, Norditropin, Saizen, Omnitrope, Nutropin, Zomacton) and the three long-acting analogs (Sogroya/somapacitan, FDA-approved for adult GHD in August 2020 and pediatric GHD in April 2023; Ngenla/somatrogon, approved for pediatric GHD in 2023; Skytrofa/lonapegsomatropin, approved for pediatric GHD in August 2021). Notably absent from this list: anti-aging, athletic performance, body composition in non-deficient adults, and any indication that would map onto how somatropin is most commonly discussed in biohacker contexts.

The clinical efficacy evidence in approved-indication populations is strong. The foundational adult-GHD trial (Salomon et al., N Engl J Med 1989, 321:1797–1803; n=24 double-blind placebo-controlled, daily subcutaneous rhGH 0.07 U/kg for six months) reported a mean lean body mass increase of 5.5 ± 1.1 kg and a fat mass decrease of 5.7 ± 0.9 kg in the treatment arm — body-composition changes an order of magnitude larger than what any GH-secretagogue trial has subsequently produced in any population. The companion functional study (Cuneo et al., J Appl Physiol 1991, 70:688–694) in the same 24-patient cohort documented significant increases in thigh and quadriceps cross-sectional area and in hip-flexor and limb-girdle strength after six months. Those two papers, together, established adult GH deficiency as a clinical syndrome and somatropin replacement as the standard of care — a regulatory and clinical-practice pattern that the 2016 GH Safety Workshop position paper from ESPE, GRS, and PES (Allen et al., Eur J Endocrinol 2016, 174:P1–P9) reaffirmed across pediatric, transition-age, and adult indications, with the consensus that the long-term safety record in indicated populations does not support broad cancer-incidence or mortality signal at standard replacement doses.

The biohacker question — should the GH-axis secretagogue stack (ipamorelin plus CJC-1295, or MK-677, or tesamorelin, or sermorelin) be used to amplify endogenous GH, or should somatropin be used directly? — is the framing question this page exists to address. The pharmacological trade-off has four components. Direct somatropin produces the largest effect on body-composition surrogate endpoints in any population studied. The secretagogues are smaller-effect but preserve, to varying degrees, the pulsatile somatostatin-gated feedback architecture of native GH release. Direct somatropin is dramatically more expensive at retail U.S. prescription cost — typically several hundred to several thousand dollars per month depending on dose and brand, with annual costs commonly running into five-figure territory and substantially higher for the long-acting analogs. And, most consequentially, off-label distribution of somatropin sits under 21 U.S.C. § 333(e), a 1990 amendment to the Federal Food, Drug, and Cosmetic Act that makes distribution of human growth hormone for any indication other than an HHS-authorized one a criminal offense punishable by up to five years imprisonment and DEA-investigated enforcement — a restriction unique among prescription drugs.

The literature on somatropin use in healthy non-deficient adults — the population biohacker GH protocols actually target — runs through the Rudman et al., N Engl J Med 1990, 323:1–6 trial and its corrective sequels. Rudman randomized 21 healthy men aged 61–81 with baseline IGF-1 below 350 U/L: 12 received rhGH 0.03 mg/kg three times weekly for six months; 9 served as untreated controls. The treatment group showed an 8.8% increase in lean body mass, a 14.4% decrease in adipose mass, and a 1.6% increase in vertebral bone mineral density — and that single 12-subject, 6-month, no-placebo, surrogate-endpoint trial became the foundational citation for the entire "GH as anti-aging therapy" market. The follow-up safety paper (Cohn et al., Clin Endocrinol 1993, 39:417–425) documented carpal tunnel syndrome in 10 of the treated subjects, gynecomastia in 4, and hyperglycemia in 3 — a side-effect profile the original Rudman paper had not foregrounded. The definitive correction came in Liu et al., Ann Intern Med 2007, 146:104–115: a systematic review of 18 randomized controlled trials in 508 healthy elderly adults that reported a 2.13 kg increase in lean body mass and a 2.08 kg decrease in fat mass with somatropin — but no significant change in body weight, and significantly higher rates of soft-tissue edema, carpal tunnel syndrome, arthralgias, and gynecomastia. The authors concluded that GH "cannot be recommended as an anti-aging therapy." The /critic/sermorelin-naturalistic-fallacy and /critic/peptide-stacking-multiplied-effects responses address adjacent framing claims the GH-secretagogue conversation routinely makes.

The sociological context completes the picture. The 1999 Genentech $50 million settlement for off-label Protropin promotion in non-deficient short children, the 2005 Serono $704 million settlement over Serostim promotion in HIV wasting, and the 2007 Pfizer $34.7 million settlement over Genotropin marketing are the regulatory-enforcement record that shaped the modern compliance environment around somatropin (HGH controversies, Wikipedia). The off-label-prohibition regime is the legal-landscape reason the biohacker GH-axis conversation defaults to compounded secretagogues rather than to somatropin itself. The wada-prohibited-status-registry covers the sport-doping side: somatropin is unambiguously prohibited at all times under WADA S2.2, with the Athlete Biological Passport endocrine module catching it through IGF-1 and P-III-NP markers even when direct-detection windows are missed.

The honest framing for this page has three parts. Somatropin is the best-characterized GH-axis intervention in the literature, with FDA approvals across multiple specific deficiency indications and a long safety record in those populations. The regulatory-grade evidence base in healthy non-deficient adults — the population biohacker protocols target — runs through the Rudman–Cohn–Liu sequence and arrives at a measured conclusion: modest body-composition shifts, real adverse-event burden, no support for anti-aging or general-population use. And every secretagogue claim of "physiological GH pulse" or "natural endogenous release" is making an implicit comparison to somatropin — yet the trial-grade evidence that secretagogue stacks produce better outcomes than direct somatropin in healthy adults, or that they produce comparable outcomes at lower side-effect burden, does not exist in any large randomized controlled trial as of 2026.